But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to ...

Danish pharma major Novo Nordisk on Friday launched its blockbuster type 2 diabetes treatment injection Ozempic, globally popular for its weight-loss benefits. Ozempic is now available in India as ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 (approx ₹ 2,200) per week, as it seeks ...

Danish pharmaceutical company Novo Nordisk today launched its blockbuster type 2 diabetes treatment injection Ozempic in ...

The drug is marketed globally by Novo Nordisk as Ozempic for Type 2 diabetes and for obesity, and has been at the centre of a ...

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor ...

Novo Nordisk on Friday launched its blockbuster weight-loss drug Ozempic in India, beginning at Rs 8,800 a month or four ...

Novo Nordisk A/S left open the door for additional work on its pill version of Ozempic for Alzheimer’s disease after a pair of failed trials, saying that patients showed a biological response in a ...

There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...